Displaying drugs 551 - 575 of 15268 in total
Pentostatin
A potent inhibitor of adenosine deaminase. The drug is effective in the treatment of many lymphoproliferative malignancies, particularly hairy-cell leukemia. It is also synergistic with some other antineoplastic agents and has immunosuppressive activity.
Approved
Investigational
Matched Description: … It is also synergistic with some other antineoplastic agents and has immunosuppressive activity. …
Matched Categories: … Nucleic Acid Synthesis Inhibitors ... Antineoplastic and Immunomodulating Agents ... Nucleic Acids, Nucleotides, and Nucleosides …
Matched Categories: … Nucleic Acid Synthesis Inhibitors ... Antineoplastic and Immunomodulating Agents ... Nucleic Acids, Nucleotides, and Nucleosides …
Ethanolamine oleate
Ethanolamine oleate is a mild sclerosing agent. It is composed of ethanolamine, a basic substance, which when combined with oleic acid forms a clear, straw to pale yellow colored, deliquescent oleate.
Approved
Matched Iupac: … (9Z)-octadec-9-enoic acid; 2-aminoethan-1-ol …
Matched Description: … It is composed of ethanolamine, a basic substance, which when combined with oleic acid forms a clear, …
Matched Description: … It is composed of ethanolamine, a basic substance, which when combined with oleic acid forms a clear, …
Regadenoson
Regadenoson is an A2A adenosine receptor agonist that causes coronary vasodilation and used for myocardial perfusion imagining. Manufactured by Astellas and FDA approved April 10, 2008.
Approved
Investigational
Matched Description: … Manufactured by Astellas and FDA approved April 10, 2008. ... Regadenoson is an A2A adenosine receptor agonist that causes coronary vasodilation and used for myocardial …
Secnidazole
Secnidazole is a second-generation 5-nitroimidazole antimicrobial agent. It is structurally related to other 5-nitroimidazoles, including DB00916 and DB00911, but displays improved oral absorption and a longer terminal elimination half-life than other drugs in this class. Secnidazole is selective against many anaerobic Gram-positive and Gram-negative bacteria as well as protozoa. Once...
Approved
Matched Description: … [A245503, A245508] In September 2017, FDA approved secnidazole under the market name Solosec for the ... treatment of trichomoniasis and bacterial vaginosis. ... to form a radical anion, thereby damaging and killing the target pathogen. …
Matched Categories: … azithromycin, fluconazole and secnidazole ... Antiparasitic Products, Insecticides and Repellents …
Matched Categories: … azithromycin, fluconazole and secnidazole ... Antiparasitic Products, Insecticides and Repellents …
Pralsetinib
Pralsetinib, similar to the previously approved selpercatinib, is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A219751, L15986] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers, including non-small cell lung cancer. Although multikinase inhibitors, including cabozantinib, ponatinib,...
Approved
Investigational
Matched Description: … Pralsetinib, similar to the previously approved [selpercatinib], is a kinase inhibitor with enhanced ... Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and ... [A202055] Pralsetinib (BLU-667) and [selpercatinib] (LOXO-292) represent the first generation of specific …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Baricitinib
Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated inflammation and immune responses. Baricitinib was...
Approved
Investigational
Matched Description: … of rheumatoid arthritis in adults [A248395] and was later approved by the FDA in 2018. ... By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated inflammation and immune ... [A248400] The EC later approved baricitinib for the treatment of atopic dermatitis, making it the first …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Histrelin
Histrelin is a gonadotropin-releasing hormone (GnRH) agonist that acts as a potent inhibitor of gonadotropin when administered as an implant delivering continuous therapeutic doses. This drug is a synthetic analog of naturally occurring GnRH with a higher potency. Histrelin implants are non-biodegradable, diffusion-controlled, hydrogel polymer reservoirs containing histrelin acetate that...
Approved
Withdrawn
Matched Iupac: … propanamido]-4-methylpentanamido]-5-carbamimidamidopentanoyl]-N-ethylpyrrolidine-2-carboxamide; bis(acetic acid …
Matched Description: … treatment for children with central precocious puberty (CPP) due to their capacity to reduce LH levels and ... As the product Supprelin LA, histrelin is indicated for the treatment of CPP in children (approved by ... [L41715] The Vantas product was approved by the FDA in October 2004 for the palliative treatment of this …
Matched Categories: … Hormones and Related Agents ... Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Matched Description: … treatment for children with central precocious puberty (CPP) due to their capacity to reduce LH levels and ... As the product Supprelin LA, histrelin is indicated for the treatment of CPP in children (approved by ... [L41715] The Vantas product was approved by the FDA in October 2004 for the palliative treatment of this …
Matched Categories: … Hormones and Related Agents ... Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Oritavancin
Oritavancin is a glycopeptide antibiotic used for the treatment of skin infections. It was developed by The Medicines Company (acquired by Novartis). Oritavancin was initially approved by the FDA in 2014 and formulated to combat susceptible gram-positive bacteria that cause skin and skin structure infections. It boasts the option of...
Approved
Investigational
Matched Iupac: … }.0^{34,39}]pentaconta-3,5,8,10,12(48),14,16,29(45),30,32,34,36,38,46,49-pentadecaene-40-carboxylic acid …
Matched Description: … [L12858] Oritavancin was initially approved by the FDA in 2014 and formulated to combat susceptible gram-positive ... [A39384,A193482,L8492] On March 12, 2021 the FDA approved Kimyrsa, a complete course of therapy in ... [L32634] Orbactiv, the other FDA approved oritavancin product, is administered over a 3 hour infusion …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Matched Description: … [L12858] Oritavancin was initially approved by the FDA in 2014 and formulated to combat susceptible gram-positive ... [A39384,A193482,L8492] On March 12, 2021 the FDA approved Kimyrsa, a complete course of therapy in ... [L32634] Orbactiv, the other FDA approved oritavancin product, is administered over a 3 hour infusion …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Safinamide
Safinamide is for the treatment of parkinson's disease. It was approved in Europe in February 2015, and in the United States on March 21, 2017.
Approved
Investigational
Matched Description: … It was approved in Europe in February 2015, and in the United States on March 21, 2017. …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Disopyramide
A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties.
Approved
Matched Description: … It also possesses some anticholinergic and local anesthetic properties. ... anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and …
Gallium Ga-68 gozetotide
Gallium (Ga) 68 prostate-specific membrane antigen (PSMA)-11, or Ga-68 gozetotide, is a radiopharmaceutical agent used to identify and assess prostate-specific membrane antigen (PSMA)-positive lesions in adult men with prostate cancer during positron emission tomography (PET). Prostate cancer is one of the most commonly diagnosed cancers among men in Western countries...
Approved
Matched Description: … L26981] Prostate cancer is one of the most commonly diagnosed cancers among men in Western countries and ... [L27006]
On December 1, 2020, Ga-68 PSMA-11 was approved by the FDA as the first molecular-targeted ... prostate-specific membrane antigen (PSMA)-11, or Ga-68 gozetotide, is a radiopharmaceutical agent used to identify and …
Matched Categories: … Indicators and Reagents …
Matched Categories: … Indicators and Reagents …
Dostarlimab
Dostarlimab is an IgG4 humanized monoclonal antibody targeted against the human programmed death receptor-1 (PD-1). PD-1 receptors are found on T-cells and, when activated, serve to inhibit immune responses - some cancers leverage this system by overexpressing PD-1 ligands, thereby effectively inhibiting the anti-tumor immune response that would typically attempt...
Approved
Investigational
Matched Description: … [L33340] A companion diagnostic device - the VENTANA MMR RxDx Panel - was also approved alongside this ... those of the skin, lung, kidneys, and liver. ... [L33320] PD-1 receptors are found on T-cells and, when activated, serve to inhibit immune responses - …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Reviparin
Reviparin is a low molecular weight heparin which seems to have a better safety profile than unfractionated heparin. It is prepared from porcine intestinal mucosa by nitrous acid depolymerization. Reviparin has a molecular weight of 3.9 kDa. It was developed by Abbott laboratories and in 2009, reviparin presented an orphan...
Approved
Investigational
Matched Description: … [A32019] It is prepared from porcine intestinal mucosa by nitrous acid depolymerization. ... [A32021] It was developed by Abbott laboratories and in 2009, reviparin presented an orphan drug designation …
Matched Categories: … Heparin and similars ... Blood and Blood Forming Organs …
Matched Categories: … Heparin and similars ... Blood and Blood Forming Organs …
Lifitegrast
Lifitegrast is a FDA approved drug for the treatment of keratoconjunctivitis sicca (dry eye syndrome). It is a tetrahydroisoquinoline derivative and lymphocyte function-associated antigen-1 ( LFA-1) antagonist that was discovered through the rational design process. The ophthalmic solution was approved in July, 2016 under the trade name Xiidra. It has...
Approved
Matched Iupac: … carbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinolin-6-yl]formamido}-3-(3-methanesulfonylphenyl)propanoic acid …
Matched Description: … The ophthalmic solution was approved in July, 2016 under the trade name Xiidra. ... Lifitegrast is a FDA approved drug for the treatment of keratoconjunctivitis sicca (dry eye syndrome) ... onset of action and well tolerated profile in both local and systemic setting [A18805]. …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Matched Description: … The ophthalmic solution was approved in July, 2016 under the trade name Xiidra. ... Lifitegrast is a FDA approved drug for the treatment of keratoconjunctivitis sicca (dry eye syndrome) ... onset of action and well tolerated profile in both local and systemic setting [A18805]. …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Nylidrin
Nylidrin, also known as buphenine belongs to the category of drugs called vasodilators, which relax blood vessels and increase blood flow. Nylidrin is a peripheral vasodilator. Some studies show the evidence of improving cognitive impairment in selected individuals, such as geriatric patients with mild to moderate symptoms of cognitive, emotional...
Approved
Matched Description: … known as _buphenine_ belongs to the category of drugs called _vasodilators_, which relax blood vessels and ... This effect may help to improve memory/judgment, improve walking ability, and support the healing of ... selected individuals, such as geriatric patients with mild to moderate symptoms of cognitive, emotional and …
Matched Categories: … Genito Urinary System and Sex Hormones …
Matched Categories: … Genito Urinary System and Sex Hormones …
Articaine
Articaine is a dental local anesthetic. Articaine is widely used around the world and is the most popular local anesthetic in many European countries.
Approved
Matched Description: … Articaine is widely used around the world and is the most popular local anesthetic in many European countries …
Matched Mixtures name: … Septocaine and Epinephrine ... Septocaine and Epinephrine ... Articaine HCl and Epinephrine …
Matched Mixtures name: … Septocaine and Epinephrine ... Septocaine and Epinephrine ... Articaine HCl and Epinephrine …
Deflazacort
Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label]
Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dystrophin gene, which...
Approved
Investigational
Matched Description: … It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA. ... This disease can cause serious muscle weakness and progressive breathing and cardiovascular disability ... , severely impacting patient quality of life and survival. …
Matched Categories: … Sex Hormones and Insulins …
Matched Categories: … Sex Hormones and Insulins …
Alfuzosin
Benign prostatic hyperplasia (BPH) refers to a benign growth or hyperplasia of the prostate and leads to lower urinary tract symptoms in men, such as urgency, frequency and changes to urine flow. The prevalence of BPH is as high as 50%-60% for males in their 60's, and this prevalence increases...
Approved
Investigational
Matched Description: … [L31593] It was initially approved by the FDA in 2003 and is marketed by several pharmaceutical companies ... Benign prostatic hyperplasia (BPH) refers to a benign growth or hyperplasia of the prostate and leads ... to lower urinary tract symptoms in men, such as urgency, frequency and changes to urine flow. …
Matched Categories: … alfuzosin and finasteride ... Genito Urinary System and Sex Hormones …
Matched Categories: … alfuzosin and finasteride ... Genito Urinary System and Sex Hormones …
Florbetapir (18F)
Florbetapir (18F) is a radiopharmaceutical compound containing the radionuclide fluorine-18 bound to the compound florbetapir, a molecule that binds with high affinity to beta amyloid plaque, a peptide that plays a key role in Alzheimer's Disease pathogenesis. Marketed as the product Amyvid, florbetapir 18F is indicated for positron emission tomography...
Approved
Investigational
Matched Description: … density in adult patients with cognitive impairment who are being evaluated for Alzheimer's Disease (AD) and …
Turoctocog alfa pegol
Turoctocog alfa pegol is a pegylated version of turoctocog alfa. Novo Nordisk's brand name Esperoct (turoctocog alfa pegol, N8-GP) was approved by the US FDA on February 19, 2019.
Fundamentally, the N8-GP moiety is identical to turoctocog alfa, a recombinant human clotting factor VIII (rFVIII) with a truncated B-domain made...
Approved
Matched Description: … It was developed by Novo Nordisk and approved by the US FDA on October 16, 2013 [L1104]. ... During secretion, some rFVIII molecules are cleaved at the C-terminal of the heavy chain (HC) at amino acid ... Novo Nordisk's brand name Esperoct (turoctocog alfa pegol, N8-GP) was approved by the US FDA on February …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Pimethixene
Pimethixene is approved for use in Brazil and is marketed under the trade name Muricalm. It is an anticholinergic used in the treatment of bronchitis.
Approved
Matched Description: … Pimethixene is approved for use in Brazil and is marketed under the trade name Muricalm. …
Cilgavimab
SARS-CoV-2, the causative agent of COVID-19, enters cells via the interaction between the trimeric spike (S) glycoprotein and host cell angiotensin-converting enzyme 2 (ACE2). Blocking the interaction between the receptor-binding domain (RBD) of the S1 subunit and ACE2 inhibits viral host cell entry; animal studies indicate that antibodies capable of...
Approved
Investigational
Matched Description: … [L39411] EVUSHELD was granted marketing authorization by the EMA on March 28, 2022,[L41454] and was approved ... modified through targeted amino acid substitutions to exhibit an extended (~85-day) half-life. ... [A243351, A243361, L39411]
Cilgavimab is not approved for any indication by the FDA. …
Matched Categories: … tixagevimab and cilgavimab ... Amino Acids, Peptides, and Proteins ... Immune Sera and Immunoglobulins …
Matched Categories: … tixagevimab and cilgavimab ... Amino Acids, Peptides, and Proteins ... Immune Sera and Immunoglobulins …
Tixagevimab
SARS-CoV-2, the causative agent of COVID-19, enters cells via the interaction between the trimeric spike (S) glycoprotein and host cell angiotensin-converting enzyme 2 (ACE2). Blocking the interaction between the receptor-binding domain (RBD) of the S1 subunit and ACE2 inhibits viral host cell entry; animal studies indicate that antibodies capable of...
Approved
Investigational
Matched Description: … [L39411] EVUSHELD was granted marketing authorization by the EMA on March 28, 2022,[L41454] and was approved ... modified through targeted amino acid substitutions to exhibit an extended (~85-day) half-life. ... [A243351, A243361, L39411]
Tixagevimab is not approved for any indication by the FDA. …
Matched Categories: … tixagevimab and cilgavimab ... Amino Acids, Peptides, and Proteins ... Immune Sera and Immunoglobulins …
Matched Categories: … tixagevimab and cilgavimab ... Amino Acids, Peptides, and Proteins ... Immune Sera and Immunoglobulins …
Clofarabine
Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic...
Approved
Investigational
Matched Description: … Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic ... It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. ... Its potential use in acute myeloid leukaemia (AML) and juvenile myelomonocytic leukaemia (JMML) has been …
Matched Categories: … Nucleic Acid Synthesis Inhibitors ... Antineoplastic and Immunomodulating Agents ... Nucleic Acids, Nucleotides, and Nucleosides …
Matched Categories: … Nucleic Acid Synthesis Inhibitors ... Antineoplastic and Immunomodulating Agents ... Nucleic Acids, Nucleotides, and Nucleosides …
Displaying drugs 551 - 575 of 15268 in total